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Abstract
Introduction: The endocannabinoid system modulates function of immune cells and mesenchymal cells such
as fibroblasts, which contribute to cartilage destruction in rheumatoid arthritis (RA). The aim of the study was
to determine the influence of N-acylethanolamines anandamide (AEA), palmitoylethanolamine (PEA) and
oleylethanolamine (OEA) on several features of arthritic inflammation in vitro (human material) and in vivo
(a mouse model).
Methods: Immunofluorescence and western blotting were used to detect cannabinoid receptors and related
enzymes. Cytokines and MMP-3 were measured by ELISA. Intracellular signaling proteins were detected by proteome
profiling. Proliferation was quantified by CTB reagent. Adhesion was assessed by the xCELLigence system. After onset
of collagen type II arthritis, mice were treated daily with the FAAH inhibitor JNJ1661010 (20 mg/kg) or vehicle.
Results: IL-6, IL-8 and MMP-3 (determined only in synovial fibroblasts (SFs)) were downregulated in primary synoviocytes
and SFs of RA and OA after AEA, PEA and OEA treatment. In SFs, this was due to activation of TRPV1 and TRPA1 in a COX-
2-dependent fashion. FAAH inhibition increased the efficacy of AEA in primary synoviocytes but not in SFs. The effects of
OEA and PEA on SFs were diminished by FAAH inhibition. Adhesion to fibronectin was increased in a CB1-dependent
manner by AEA in OASFs. Furthermore, elevation of endocannabinoids ameliorated collagen-induced arthritis in mice.
Conclusions: N-acylethanolamines exert anti-inflammatory effects in SFs. A dual FAAH/COX-2 inhibitor, increasing
N-acylethanolamine levels with concomitant TRP channel desensitization, might be a good candidate to inhibit the
production of proinflammatory mediators of synovial cells and to reduce erosions.
Keywords: Synoviocytes, Tumor necrosis factor, Interleukin 6, Interleukin 8, Synovial fibroblasts, TRPV1, TRPA1,
Cannabinoids, Anandamide, Matrix metalloproteinase 3, Collagen-induced arthritis
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by cartilage and bone destruction [1].
Besides infiltration of lymphocytes into synovial tissue,
hyperproliferation of synovial fibroblasts (SF), which
produce matrix-degrading enzymes and proinflamma-
tory cytokines, is an important propagator of RA [2]. SF
migrate to distant sites and may thereby spread arthritis
to unaffected joints [3]. Furthermore, due to the proin-
flammatory environment in the joint, hypoxia develops,
which leads to the upregulation of a wide array of proin-
flammatory genes in RASF [4, 5]. Data from Richardson
and colleagues suggest that the synovial endocan-
nabinoid system is altered in RA. While the endocanna-
binoid arachidonylethanolamine (anandamide, AEA) and
2-archidonyl glycerol (2-AG) are absent from healthy
joints, where related N-acylethanolamines oleoylethano-
lamine (OEA) and palmitoylethanolamine (PEA) are
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abundant, both 2-AG and AEA were found in joints of
arthritic and osteoarthritic patients [6].
Endocannabinoids (EC) are neuromodulatory lipid
mediators that exert their effects mainly by activating
cannabinoid receptor type 1 (CB1) and type 2 (CB2) [7].
However, additional targets for EC and related N-
acylethanolamines were identified. These include the
transient receptor potential vanilloid channel TRPV1,
peroxisome proliferator-activated receptors α and γ but
also G protein-coupled receptors GPR18 and GPR55
>8–10>. Experiments demonstrated that some cannabin-
oid effects are attributed to activation of these receptors
10>. AEA, OEA and PEA but also <?A3B2 thyc=2-ara-
chidonylglycerol (2-AG) are produced on demand from
lipid precursors in the cell membrane [11]. Their action
is limited by degradation by either monoacylglycerol lip-
ase (MAGL, specific for 2-AG) or fatty acid amide
hydrolase (FAAH, specific for AEA, OEA and PEA) al-
though alternative routes of degradation exist. Pharma-
cological inhibition of FAAH or MAGL increases
systemic levels of the respective EC [12]. Besides their
well-characterized central effects, EC also reduce the
production of proinflammatory cytokines in various cell
types, decrease T cell proliferation and inhibit migration
of immune cells [13].
Currently, the effects of N-acylethanolamines on
production of inflammatory mediators in primary
synoviocytes or SF have not been described. In this study,
we investigate their effects on primary synoviocytes (AEA
only) but also on SF from RA and osteoarthritis (OA). It is
shown how AEA regulates tumor necrosis factor (TNF),
interleukin-6 (IL-6), interleukin-8 (IL-8) and matrix metal-
loproteinase 3 (MMP-3) production, mitogen-activated
protein (MAP) kinase signaling and SF adhesion. In
addition, the involvement of cyclooxygenase-2 (COX-
2), TRPV1 and transient receptor potential cation channel
(TRPA1) in mediating the effects of AEA but also PEA
and OEA is revealed, increasing possible therapeutic
targets for the treatment of RA. Furthermore, it is demon-
strated that systemic FAAH inhibition is beneficial in
collagen type II-induced arthritis (CIA).
Materials and methods
Patients
In this study, 28 patients with long-standing RA fulfilling
the American College of Rheumatology revised criteria
for RA [14] and 56 patients with OA were included. The
RA group comprised of 21 females and 7 males with a
mean age of 61.1 years ±10.7 years; C-reactive protein
was 7.0 mg/dl ± 8.59 mg/dl. In the RA group, 23 patients
received nonsteroidal anti-inflammatory drugs, 22 re-
ceived glucocorticoids, 11 received methotrexate, 3 re-
ceived sulfasalazine and 2 received biologicals. The OA
group comprised of 31 females and 25 males with a
mean age of 68.5 years ±9.2 years; C-reactive protein
was 4.7 mg/dl ± 10.4 mg/dl. In the OA group, 45 pa-
tients received nonsteroidal anti-inflammatory drugs. All
patients underwent elective knee joint replacement sur-
gery, and they were informed about the purpose of the
study and gave written consent. The study was approved
by the Ethics Committee of the University of
Regensburg.
Animals
Male DBA/1 mice, 6–8 weeks old, were purchased from
Janvier (Heverlee, Belgium). The mice were housed 10
animals per cage, had free access to standard laboratory
chow and water ad libitum, and were maintained under
a 12-hour light/dark cycle. Experiments were conducted
according to institutional and governmental regulations
for animal use and were approved. (Government of the
Oberpfalz AZ 54–2532.1-42/11).
Synovial fibroblast and tissue preparation
Synovial tissue samples from OA and RA were obtained
immediately after opening the knee joint capsule, the
preparation of which was described [15]. Pieces of syn-
ovial tissue of up to 9 cm2 were excised. One part of the
tissue was cut, placed in protective freezing medium and
stored at −80 °C until further use (Tissue Tek, Sakura
Finetek, Zoeterwoude, The Netherlands). Another part
was minced and treated with dispase I (Roche Diagnos-
tics, Mannheim, Germany). Digestion was carried out
for 1 h at 37 °C on a shaking platform. The resulting
suspension was filtered (70 μm) and centrifuged at 300 g
for 10 min. The pellet was then treated with erythrocyte
lysis buffer (20.7 g NH4Cl, 1.97 g NH4HCO3, 0.09 g
EDTA ad 1 l H2O) for 5 min and again centrifuged for
10 min at 300 g. The pellet was resuspended in RPMI-
1640 (Sigma-Aldrich, St. Louis, MO, USA) with 10 %
fetal calf serum (FCS).
Stimulation of RA synovial fibroblasts
To study cytokine and MMP-3 production, cells were
stimulated in 2 % serum-containing RPMI-1640 medium
with respective compounds 5 h prior to addition of TNF
(10 ng/ml final concentration). Cell culture supernatants
were used for enzyme-linked immunosorbent assays
(ELISAs) 24 h (cytokines) or 48 h (MMP-3) after
addition of compounds.
TNF, IL-6 and IL-8 ELISA
Tests were conducted as described by the supplier (BD
OptEIA, BD Biosciences, Heidelberg, Germany). Super-
natants from SF were diluted 1:13 (SF), 1:400 (primary
synoviocytes) (for IL-6 and IL-8) or used undiluted
(TNF) before use. Inter- and intra-assay coefficient of
variation was below 10 %.
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Matrix metalloproteinase-3 (MMP-3) ELISA
A total of 100 μl of tissue culture supernatants were
transferred into 96-well plates (NUNC, Langenselbold,
Germany) for 3 h at 37 degrees. Supernatants were
removed and 1 % bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) was added for 1 h at
room temperature to block unspecific binding. Then,
anti-MMP3 (ab52915, Abcam, Cambridge, UK) antibody
was added for 1 h at room temperature (1:1000, diluted
in PBS with 1 % BSA). After washing, secondary anti-
body (1:2000, goat anti-rabbit poly-horseradish peroxid-
ase (HRP), Fisher Scientific, Schwerte, Germany) was
added for 1 h at room temperature. Standard MMP-3
protein was obtained from R&D Systems (Wiesbaden,
Germany).
Monitoring adhesion with the xCELLigence system
This system has been previously described [16]. For
adhesion experiments, E-plates (Roche Diagnostics,
Mannheim, Germany) were coated for 1 h at room
temperature with 100 μl 10 μg/ml fibronectin (BD Bio-
sciences, Heidelberg, Germany) in PBS. To block unspe-
cific binding, 1 % BSA in PBS was added for 30 min. A
total of 5000 pretreated cells (see above) were added to
the E-plates and xCELLigence was programmed to
monitor adhesion every minute for 240 min. After
60 min of incubation, adhesion remained linear so that
this time point was chosen as the endpoint of adhesion
measurement. Adhesion was quantified by averaging
data from 1 min to 60 min of incubation. Untreated cells
served as control and this value was set to 100 %.
Immunocytochemistry
The following antibodies (all from Abcam, Cambridge,
UK and Serotec (FAAH), Puchheim, Germany) were
used: CB1 (ab23703, 30 μg/ml), CB2 (30 μg/ml, ab3561),
TRPV1 (ab63083, 1:300), TRPA1 (ab62053, 30 μg/ml),
COX-2 (ab62331, 30 μg/ml), and FAAH (MCA3101Z,
30 μg/ml). Cells were fixed with 3.7 % formaldehyde and
permeabilized with 0.1 % Triton-X 100 in PBS. Slides
were blocked with 1 % BSA in PBS/0.1 % Triton-X and
incubated with primary antibody 3 h at 37 °C. Cells were
washed and incubated with secondary cyanine-
conjugated goat anti-rabbit antibody (1:500, Cy™3,
Jackson Immunoresearch, West Grove, PA, USA) over-
night at 4 °C. Isotype immunoglobulin G (IgG) or rabbit
serum (TRPV1) served as negative control.
Western blotting
The following antibodies (all from Abcam, Cambridge,
UK and Serotec (FAAH), Puchheim, Germany) were used:
CB1 (ab23703, 0.5 μg/ml), CB2 (ab3561, 1 μg/ml), TRPV1
(ab111973, 1 μg/ml), COX-2 (ab62331, 0.4 μg/ml), FAAH
(serotec, MCA3101Z, 1 μg/ml), superoxide dismutase 2
(SOD-2) (Lab Frontier, Seoul, Korea, LF-PA0021, 1:2000),
poly(ADP-ribose) polymerase (PARP) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (Cell Signaling,
Leiden, Netherlands, #9542 and #2118, 1:1000). A total of
1,000,000 cells were lysed with RIPA buffer (10 mM
Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1 % Triton
X-100, 0.1 % sodium deoxycholate, 0.1 % SDS, 140 mM
NaCl, complete protease inhibitor (Roche Diagnostics,
Mannheim, Germany)) and protein content was deter-
mined. Gels (separation gel: 15 % acrylamide) were loaded
with 20–50 μg protein and run for 60 min at 20 mA (Bio-
Rad Laboratories, Puchheim, Germany). Gels were blotted
at 80 V for 90 min on PVDF membranes (Bio-Rad Labora-
tories, Puchheim, Germany). Gels were blocked with 5 %
nonfat dried milk in Tris-buffered saline (TBS) for 1 h.
Primary antibodies were added overnight at 4 °C, whereas
detection antibodies (donkey anti-rabbit IgG HRP
(Dianova, Hamburg, Germany) 711-035-152, 1:5000)) were
added afterwards for 1 h at room temperature. Signal was
detected by ECL Prime (GE Healthcare, Freiburg,
Germany) and analyzed in a V3 Western Workflow (Bio-
Rad Laboratories, Puchheim, Germany).
Proteom profiling (detection of phosphorylation status of
selected MAP kinases)
For the assessment of MAP kinase activation we
employed the proteome profiler human phospho-MAPK
array kit (R&D Systems, Minneapolis, MN, USA,
ARY001B). This assay is a membrane-based sandwich
immunoassay and can detect 24 kinases simultaneously.
The assay was conducted as described by the supplier.
Cell-based ELISA
This test was used to quantify protein levels of CB1, CB2,
TRPV1 and TRPA1. For antibodies used see the immuno-
cytochemistry section. Final concentrations employed in
the assay were 1.5 μg/ml for CB1, CB2 and TRPA1
(TRPV1, 1:1000). Cells were fixed with 3.7 % formalde-
hyde and permeabilized with 0.1 % Triton-X 100 in PBS.
Microtiter plates were blocked with 1 % BSA in PBS/0.1 %
Triton-X and incubated with primary antibody 3 h at 37 °C.
Cells were washed and incubated with secondary poly
HRP-conjugated goat anti-rabbit antibody (#32260, 1:5000,
Thermo Fisher Scientific, Waltham, MA, USA) for 2 h at
room temperature. Staining was visualized with 1-step
Ultra TMB (#34029, Thermo Fisher Scientific).
Induction of arthritis and scoring
Experiments were performed as previously described by
our group [17]. Briefly, on day 0, mice were immunized
intradermally at the base of the tail with 100 μg of bo-
vine collagen type II (Chondrex, Redmond, WA, USA)
emulsified in an equal volume of Freund’s complete adju-
vant (Sigma-Aldrich, Deisenhofen, Germany). Each limb
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was graded separately, and points were given according to
various inflamed regions: toes (0.5–2.5), midpaw (0.5–2.5),
and wrist/ankle (0.5–2.5). Thus, a maximum total score of
15 points per extremity and 60 points per animal was
given.
Treatment of animals
Treatment was started when animals reached a score of
four points. Daily injections of either FAAH inhibitor
JNJ1661010 (R&D Systems, Wiesbaden, Germany) or ve-
hicle were given intraperitoneally (i.p.) JNJ1661010 was
dissolved in 20 % Pharmasolve (N-methyl-2-pyrrolidone;
Sigma-Aldrich, Taufkirchen, Germany), 5 % cremophor
(Sigma-Aldrich, Taufkirchen, Germany) and 75 % PBS.
Reagents
Anandamide, oleoylethanolamide, palmitoylethanolamide,
N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)-1-piperazine-
carboxamide (JNJ1661010), cyclohexylcarbamic acid
3'-(Aminocarbonyl)-[1,1'-biphenyl]-3-yl ester (URB597),
5-[(1,1'-Biphenyl]-4-yl)methyl]-N,N-dimethyl-1H-tetrazole-
1-carboxamide (Ly2183240), N-(4-nitro-2-phenoxyphenyl)-
methanesulfonamide (nimesulide), 1-[8-(2-chlorophenyl)-9-
(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4
-carboxamide hydrochloride (CP945598), N-(1,3-benzo-
dioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentylo-
xy)-3-quinolinecarboxamide (JTE-907), N-[2-(4-chlorophe-
nyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzaze-
pine-2-carbothioamide (capsazepine), 6,7-deepoxy-6,7-
didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)-daph-
netoxin,20-(4-hydroxy-5-iodo-3-methoxybenzeneacetate)
(5’-iodoresiniferatoxin), (1E,3E)-1-(4-fluorophenyl)-2-me-
thyl-1-pentene-3-one oxime (A967079) were obtained
from R&D Systems/Tocris (Wiesbaden, Germany).
Concentrations of respective drugs are given in each
figure. A967079, capsazepine, nimesulide, JNJ1661010,
CP945598, JTE-907 and 5’-iodoresiniferatoxin were used
in concentrations that guaranteed maximal inhibition of
the specified target protein. These data were either gath-
ered from experiments described in the literature, already
published EC50 data or our own previous experiments.
AEA, OEA and PEA were used from 10−12/10−11 M to 10
−6 M since these compounds bind a wide variety of target
receptors with different affinities and a bell-shaped curve
was therefore expected.
Statistical analysis
Statistical analysis was performed with SigmaPlot 12
(Systat Software Inc., San Jose, CA, USA) and SPSS 20
(IBM, Armonk, NY, USA). The statistical tests used are
given in the figure legends. Statistical significance was
obtained with p values <0.05.
Results
Anandamide reduces IL-6, IL-8 and TNF production by pri-
mary mixed synoviocytes
In the first experiments, the effects of AEA with or with-
out FAAH inhibition on cytokine production by primary
mixed synovial cells containing fibroblasts, macrophages,
T and B lymphocytes and dendritic cells under normoxic
(20 % O2) serum-free conditions were determined. Syno-
viocytes from donors with osteoarthritis (OA) served as
a nonchronic inflammatory control.
Under these conditions, AEA (at 10−6 M and 10−8 M)
and concomitant FAAH inhibition with JNJ1661010
(1 μM) reduced the production of IL-6 and IL-8 by RA
but not OA mixed synoviocytes (Fig. 1b, d). TNF pro-
duction was augmented only by OA synoviocytes (at 10
−8 M without FAAH inhibition and 10−10 M with FAAH
inhibition) (Fig. 1e). Average control values for cytokines
(dotted line at 100 % in Fig. 1) were 110 ± 44 ng/ml
(OA) and 148 ± 49 ng/ml (RA) for IL-6, 103 ± 49 ng/ml
(OA) and 171 ± 56 ng/ml (RA) for IL-8, and 66 ± 68 pg/
ml (OA) and 163 ± 166 pg/ml (RA) for TNF.
Synovial fibroblasts express several receptors and
enzymes involved in endocannabinoid action
In subsequent experiments, RASF generated from pri-
mary synovial cells were investigated, since effects of
AEA were only augmented in mixed RA synoviocytes
(see above). AEA, PEA and OEA bind a wide array of re-
ceptors and enzymes and, therefore, expression of pos-
sible target proteins was assessed in RASF (Fig. 2).
Immunocytochemistry and western blotting (not for
TRPA1, since antibodies were not suitable for western
blotting) revealed that RASF not only express CB1, CB2,
FAAH and COX-2 but also TRPV1 and TRPA1 (Fig. 2a-
f ) (see also Figure S1 in Additional file 1 for entire blots
and blocking peptide control). Surprisingly, CB1 was
found located exclusively in the nuclear membrane
(Fig. 2a). Addition of TNF (10 ng/ml, 48 h) and hypoxia
influenced protein levels of CB1, CB2, TRPV1 and
TRPA1 (Fig. 2g-j). CB1 and CB2 protein were increased
by TNF treatment (Fig. 2g, h). TRPV1 and TRPA1 were
significantly increased in RASF when hypoxia was com-
bined with TNF treatment (Fig. 2i, j).
Anandamide reduces TNF-induced IL-6, IL-8 and MMP-3
production by RASF in a TRPA1-dependent manner
SF contribute not only to erosions in RA but also fuel
inflammation by producing large amounts of cytokines
and chemokines [18]. MMP-3 production served as an
additional read-out because this MMP is abundantly
produced by SF upon cytokine challenge and is a major
contributor to erosions in RA [19]. All experiments with
isolated SF were conducted under hypoxic conditions
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(1 % O2), since this represents the oxygen partial pres-
sure in synovial tissue [4].
In the presence of TNF (10 ng/ml), AEA preincuba-
tion (5 h, 10−6 M to 10−12 M) significantly reduced IL-6,
IL-8 and MMP-3 production by RASF (Fig. 3a, c, e).
The effects of AEA on TNF-induced IL-6, IL-8 and
MMP-3 production were not abrogated by CB1, CB2 or
TRPV1 antagonism (Figure S2 in Additional file 2).
However, the TRPA1 antagonist A967079 (10−6 M)
blocked the inhibitory effects of AEA on TNF-induced
IL-6 (Fig. 3a) and IL-8 (Fig. 3c) but not on MMP-3 pro-
duction (Fig. 3e) in RASF. The effect of AEA together
with A967079 on IL-6 and IL-8 production were inhib-
ited when combined with the COX-2 inhibitor nimesu-
lide (10−6 M) (Fig. 3b, d). MMP-3 production by RASFs
was significantly reduced when A967079 was combined
with AEA (Fig. 3e). This effect was attenuated by the
addition of nimesulide (Fig. 3f ). Since inhibition of
FAAH and the putative AEA transporter enhance the
effects of AEA [20, 21], we also combined AEA with
the dual FAAH inhibitor/AEA transport inhibitor
Ly2183240 (10−7 M). However, in contrast to mixed syn-
ovial cell cultures, the effects of AEA on TNF-induced
cytokine production were not enhanced by FAAH inhib-
ition in RASF (data not shown). Average control values
(dotted line at 100 % in Fig. 3) were 3.82 ± 2.68 ng/ml
for IL-6, 3.60 ± 1.58 ng/ml for IL-8 and 42 ± 17 ng/ml
for MMP-3.
Anti-inflammatory activity of N-acylethanolamines PEA
and OEA are also mediated by TRP channels
The AEA congeners OEA and PEA are also activators/
desensitizers at TRPV1 channels and we therefore tested
whether cation channels might be general targets of N-
acylethanolamines in SF. While OEA (10−11 M to 10−6
M) by itself did not modulate IL-6, IL-8 and MMP-3
production (Fig. 4a, c, e, black curves), combination with
the COX-2 inhibitor nimesulide significantly reduced
cytokine and MMP-3 production (Fig. 4a, c, e, red
curves). A combination of OEA and the FAAH inhibitor
JNJ1661010 (100nM) had no effect on IL-6, IL-8 and
MMP-3 secretion by RASF (data not shown). Similar to
its effects in combination with AEA, the TRPA1 antag-
onist A967079 (1 μM) blocked the effects of nimesulide/
OEA on TNF-induced IL-8 production (Fig. 4e, blue
curve). In addition, the TRPV1 anatgonist capsazepine
(1 μM) together with nimesulide/OEA also modulated
IL-8 production by RASF (Fig. 4d).
PEA (10−11 M to 10−6 M) alone significantly reduced
IL-6 and IL-8 secretion by RASF (Fig. 5a, c, e). FAAH
inhibition did not increase but slightly attenuated effects
of PEA on IL-8 production by RASF (data not shown).
Fig. 1 Influence of anandamide (AEA) with or without fatty acid amide hydrolase (FAAH) inhibition. Effects are described on IL-6 (a, b), IL-8 (c, d)
and TNF (e, f) production in RA mixed synovial cell cultures. Cytokine production was determined under normoxic (20 % O2) conditions. *p <0.01
vs. control (100 %). Mann-Whitney U test was used for comparisons between groups; paired t test was used for comparisons vs. control. All data
are given as box and vertical dot blots. The boundary of the box closest to zero indicates the 25th percentile, the line within each box indicates
the median and the upper boundary of the box the 75th percentile. Error bars below and above the box indicate the 10th and 90th percentiles.
Blue color represents treatment with the FAAH inhibitor JNJ1661010 (1 μM). IL-6 interleukin-6, IL-8 interleukin-8, RA rheumatoid arthritis, TNF tumor
necrosis factor
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In contrast to OEA, COX-2 inhibition by nimesulide did
not enhance the effects of PEA on IL-6, IL-8 and MMP-
3 production (Fig. 5a, c, e, red curves). However, when
nimesulide and PEA were combined with the TRPA1 in-
hibitor A967079 (1 μM), anti-inflammatory effects of
PEA/nimesulide on IL-6, IL-8 and MMP-3 were
Fig. 2 N-acylethanolamine binding receptors visualized by western blotting and immunofluorescence and quantification of CB1, CB2, TRPV1 and
TRPA1 in response to hypoxia and TNF in RASF by cell-based ELISA. Immunofluorescent staining and western blotting revealed the cellular
localization of CB1 (a), CB2 (b), TRPA1 (c), TRPV1 (d), FAAH (e) and COX-2 (f) protein. Original magnification is 400×. Quantification of CB1 (g), CB2
(h), TRPA1 (i) and TRPV1 (j) protein by cell-based ELISA after culture of RASF for 48 h under either hypoxia, TNF stimulation (10 ng/ml) or hypoxia
combined with TNF (10 ng/ml) in RASF. g-j: Data are given as % of unstimulated control RASF. *p <0.05 vs. normoxic control (dotted line). Paired
Wilcoxon test was used for comparisons. LY = complete cell lysate, CF = cytosolic fraction, NF = nuclear fraction, N = normoxia, H = hypoxia,
PARP = poly(ADP-ribose)-polymerase 1 (control for nuclear localization), GAPDH = glycerinaldehyd-3-phosphat-dehydrogenase (control for cytosolic
localization). CB1 cannabinoid receptor type 1, CB2 cannabinoid receptor type 2, COX-2 cyclooxygenase-2, ELISA enzyme-linked immunosorbent
assay, FAAH fatty acid amide hydrolase, IL-6 interleukin 6, IL-8 interleukin 8, MMP-3 matrix metalloproteinase 3 (stromelysin), RA rheumatoid arthritis, SF
synovial fibroblast(s), TNF tumor necrosis factor, TRPA1 transient receptor potential ankyrin 1, TRPV1 Transient receptor potential vanilloid channel
Lowin et al. Arthritis Research & Therapy  (2015) 17:321 Page 6 of 14
inhibited (Fig. 5b, d, f, blue curves). Furthermore, TRPV1
antagonism by capsazepine (1 μM) attenuated effects of
PEA/nimesulide on IL-8 production (Fig. 5d, green curve).
Nimesulide, capsazepine and A967079 alone had no effect
on RASF cytokine and MMP-3 production.
Endocannabinoids regulate intracellular signaling in SF
To address the question how EC modulate proinflamma-
tory cytokine signaling, proteome profiling was employed
to detect changes in phosphorylation of proinflammatory
intracellular signaling proteins. Preincubation of SF with
Fig. 3 Influence of anandamide (AEA) on TNF-induced (10 ng/ml) IL-6 (a, b), IL-8 (c, d) and MMP-3 (e, f) production by RASF under hypoxic
conditions. The dotted line indicates the control level of 100 % (TNF without AEA). ***p <0.001, for comparisons vs. control; p values for comparisons
between AEA/A967079 and AEA/A967079/nimesulide are given in the graph. n.s., not significant. The general linear model with Dunnett’s post hoc test
was used for all comparisons. All data are given as mean ± SEM. Cyclooxygenase-2 inhibitor = nimesulide, TRPA1 antagonist = A967079. IL-6 interleukin
6, IL-8 interleukin 8, MMP-3 matrix metalloproteinase 3 (stromelysin), RA rheumatoid arthritis, SF synovial fibroblast(s), TNF tumor necrosis factor, TRPA1
transient receptor potential ankyrin 1, TRPV1 transient receptor potential vanilloid channel
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Fig. 4 Influence of oleoylethanolamine (OEA) on TNF-induced IL-6 (a, b), IL-8 (c, d) and MMP-3 (e, f) production by RASF under hypoxic
conditions. The dotted line indicates the control level of 100 % (TNF alone). ***p <0.001 for comparisons vs. control (TNF alone); p values for
comparisons between OEA/A967079 and OEA/A967079/nimesulide or OEA/capsazepine/nimesulide are given in the graph. n.s., not significant.
The general linear model with Dunnett’s post hoc test was used for all comparisons. All data are given as mean ± SEM. TRPV1 antagonist =
capsazepine, TRPA1 antagonist = A967079, cyclooxygenase-2 inhibitor = nimesulide. IL-6 interleukin 6, IL-8 interleukin 8, MMP-3 matrix
metalloproteinase 3 (stromelysin), RA rheumatoid arthritis, SF synovial fibroblast(s), TNF tumor necrosis factor, TRPA1 transient receptor potential
ankyrin 1, TRPV1 transient receptor potential vanilloid channel
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Fig. 5 Influence of palmitoylethanolamine (PEA) on TNF-induced IL-6 (a, b), IL-8 (c, d) and MMP-3 (e, f) production by RASF under hypoxic
conditions. The dotted line indicates the control level of 100 % (TNF alone). ***p <0.001 for comparisons vs. control (TNF alone); p values for
comparisons between PEA/A967079 and PEA/A967079/nimesulide or PEA/capsazepine/nimesulide are given in the graph. n.s., not significant. The
general linear model with Dunnett’s post hoc test was used for all comparisons. All data are given as mean ± SEM. TRPV1 antagonist = capsazepine,
TRPA1 antagonist = A967079, cyclooxygenase-2 inhibitor = nimesulide. IL-6 interleukin 6, IL-8 interleukin 8, MMP-3 matrix metalloproteinase 3
(stromelysin), RA rheumatoid arthritis, SF synovial fibroblast(s), TNF tumor necrosis factor, TRPA1 transient receptor potential ankyrin 1, TRPV1 transient
receptor potential vanilloid channel
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AEA 5 h prior to TNF (10 ng/ml) treatment significantly
reduced phosphorylation of p38α (Fig. 6a) and ERK1/2
(Fig. 6c) but not cJUN (Fig. 6e) in RASF. This only oc-
curred under hypoxic but not normoxic conditions
(Fig. 6b, d).
Influence of anandamide on proliferation of OASF and
RASF
Hyperproliferation and resistance to apoptosis are two
characteristics of RASF that enhance cartilage destruc-
tion [2]. Therefore, the ability of AEA to reduce SF pro-
liferation over 96 h was assessed. Since OASF and RASF
proliferate differently (own observations), we included
OASF as control group in proliferation studies. Prolifera-
tion was conducted for 4 days under 10 % serum condi-
tions, and therefore URB597 (1 μM) was used, since this
compound guarantees prolonged FAAH inhibition. AEA
alone or in combination with the FAAH inhibitor
URB597 or the COX-2 inhibitor nimesulide did not sig-
nificantly modulate proliferation of RASF and OASF
(Fig. 7a-d). However, under hypoxic conditions, OASF
proliferation was significantly decreased when AEA was
combined with nimesulide when compared with AEA
alone (Fig. 7b). Furthermore RASF proliferated signifi-
cantly slower than OASF.
Anandamide supports adhesion of OASF and RASF to
fibronectin in a CB1-dependent manner
Our group already demonstrated the involvement of CB1
and CB2 in the adhesion of OASF and RASF to fibronec-
tin [16] and therefore the influence of AEA on this func-
tional parameter was determined. AEA significantly
increased adhesion to fibronectin over a large dose range
(10−12 M to 10−6 M) in OASF but did not reach signifi-
cance in RASF (Fig. 7e). In OASF with a trend in RASF,
this effect was significantly reduced by the CB1 antagon-
ist CP945598 (Fig. 7f ) but not by the CB2 antagonist
JTE907 (1 μM) or the TRPV1 antagonist capsazepine
(1 μM) (not shown).
Inhibition of anandamide degradation ameliorates
collagen-induced arthritis in mice
AEA reduced several inflammatory mediators and there-
fore the influence of FAAH inhibition on experimental
arthritis was investigated. Mice were injected daily with
JNJ1661010, a potent and selective inhibitor of FAAH
and treatment reduced arthritis score in comparison to
control animals (Fig. 7g).
Discussion
For the first time, it is demonstrated that N-
acylethanolamines reduce the production of inflamma-
tory mediators by OA and RA mixed synovial cells and
RASF and that AEA alters SF adhesion. Proliferation
was not altered by AEA itself but was influenced when
AEA was combined with nimesulide. These effects are
dependent on activation of the TRPA1/TRPV1 channels
and COX-2. A possible anti-inflammatory mechanism
involves downregulation of MAP kinase signaling
(p38α, ERK1/2) by AEA. Furthermore it is shown
Fig. 6 Impact of anandamide on mitogen-activated protein kinase
pathways in RASF. a-f Analysis of p38α phosphorylation (a, b), ERK1/
2 phosphorylation (c, d) and cJun phosphorylation (e, f) under TNF
treatment with or without AEA pretreatment under normoxic (a, c,
e) and hypoxic (b, d, f) conditions. Paired t test was used for
comparisons. Number of patients included was n = 4 (a, c, e) and n
= 5 (b, d, f). AEA anandamide, RA rheumatoid arthritis, SF synovial
fibroblast(s), TNF tumor necrosis factor
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that elevation of EC levels by inhibiting their degrad-
ation is beneficial in collagen-induced arthritis of the
mouse.
This study demonstrated mixed synovial cell cytokine
production was altered by AEA only when FAAH was
inhibited suggesting high AEA turnover by synoviocytes.
Fig. 7 Influence of anandamide (AEA) on proliferation and adhesion of OASF and RASF and collagen-induced arthritis in mice. (a-d) Impact of AEA on
OASF (a, b) and RASF (c, d) proliferation under normoxic (a, c) and hypoxic (b, d) conditions. e, f Adhesion of RASF and OASF to fibronectin after 24 h
treatment with AEA (e) or with AEA + CP945598 (f) under normoxic conditions. g Impact of FAAH inhibition on collagen-induced arthritis in mice. The
general linear model with Dunnett’s post hoc test was used for all comparisons. All data are given as mean ± SEM. Nimesulide = cyclooxygenase-2
inhibitor, URB597 = covalent, irreversible FAAH inhibitor, CB1 antagonist = CP945598 =, covalent, reversible FAAH inhibitor = JNJ1661010. All
antagonists/inhibitors (a-f) were used at [c] = 1 μM. FAAH fatty acid amide hydrolase, OA osteoarthritis, RA rheumatoid arthritis, SF synovial fibroblast(s)
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Reduction of lymphocyte and macrophage FAAH ex-
pression strongly increases AEA concentrations and cer-
tain threshold AEA concentrations might be necessary
to elicit anti-inflammatory effects [22].
Before evaluating the effects of AEA on RASF, screening
for possible target receptors was conducted. TRPV1 pro-
tein was detected in RASF and stimulation increased the
production of the proinflammatory cytokine IL-6 [23].
Furthermore, expression and function of several other
TRP channels have been demonstrated in RASF [24].
In addition, expression of CB1 and CB2 was demon-
strated in SF but the cellular localization was not investi-
gated [6]. This study revealed that CB2 is abundantly
expressed and embedded in the cell membrane whereas
CB1 is located almost exclusively at the nuclear mem-
brane suggesting a specialized role of CB1 in SF. Nuclear
CB1 has a unique role in mobilizing calcium from in-
ternal stores, which was revealed by intracellular admin-
istration of AEA [25].
All our studies with isolated SF regarding cytokine and
MMP-3 production have been conducted under hypoxia
(1 % O2), which reflects changes in O2 partial pressure
during chronic synovial inflammation [4].
The inhibitory effects of AEA and PEA on IL-8 produc-
tion in RASF were partially reversed by FAAH inhibition.
In addition, COX-2 inhibition enhanced the effects of the
otherwise inactive compound OEA. This suggests an
intracellular mechanism of action and demonstrates that
prolonged activity of parent compounds might have detri-
mental effects. While AEA, PEA and OEA are all sub-
strates for FAAH, only AEA is hydrolyzed by COX-2
yielding possible proinflammatory metabolites [26]. This
feature is important, since we demonstrated constitutively
high protein levels of COX-2 in SF. Therefore, AEA but
not PEA or OEA metabolism might be redirected to
COX-2 and degradation products from this reaction might
reduce the anti-inflammatory effects of AEA.
We found the effects of AEA, PEA and OEA to be
dependent on TRPA1 and TRPV1 modulation and acti-
vation of these channels have been connected to pro-
and anti-inflammatory effects depending on cell type
and setting [27]. The N-acylethanolamines OEA, PEA
and AEA have been described to bind and activate
TRPV1, but only AEA weakly activates TRPA1 in high
concentrations [28].
Importantly, our study revealed that the effects of all
three N-acylethanolamines were blocked by TRPA1 an-
tagonism and partly by TRPV1 antagonism. TRPA1 is
upregulated by hypoxia and its calcium-gating capabil-
ities are enhanced under these conditions [5, 29]. Fur-
thermore, the activity of TRPA1 is regulated by TRPV1
and possibly vice versa since there is extensive crosstalk
between these two channels via calcium [30]. In
addition, presence of both channels in one cell limits
constitutive activity and calcium leakage, while presence
of only TRPA1 increases intracellular calcium with detri-
mental effects on cellular health [30].
In our own experiments TNF was used as proinflamma-
tory stimulus to initiate cytokine production. This cyto-
kine not only enhances TRPA1 expression but also
increases COX-2 expression and initiates prostaglandin
synthesis in SF [31]. This leads to a protein kinase C-
dependent phosphorylation and sensitization of TRPV1
[32]. Given the strong interaction between TRPV1 and
TRPA1, it is likely that TNF also sensitizes TRPA1 in SF
via COX-2. Inhibition of TRPA1 with concomitant AEA,
PEA or OEA stimulation might block the desensitizing
capacity of N-acylethanolamines on TRPV1 and activation
of TRPV1 by capsaicin increases production of IL-6 [23].
Interestingly, COX-2 inhibition prevented the proin-
flammatory effects of TRPA1 antagonism with concomi-
tant AEA stimulation. In addition, the anti-inflammatory
effects of OEA and PEA combined with COX-2 inhib-
ition were blocked by TRPA1 antagonism. This suggests
that COX-2-derived prostaglandins might counteract the
desensitizing effects of AEA, OEA and PEA on TRPV1/
TRPA1. In the case of AEA, COX-2 degradation prod-
ucts (prostamides) might also influence TRPV1 or
TRPA1 activity.
A possible mechanism for the anti-inflammatory effects
of AEA is modulation of MAP kinase signaling. In this
study, it was demonstrated that AEA reduces TNF-induced
p38α and ERK1/2 phosphorylation. This phenomenon has
already been described in microglial cells, where AEA
increases the expression of MKP-1, a phosphatase and
negative regulator of MAP kinase signaling [33].
AEA has antiproliferative effects and this propensity of
cannabinoids has been investigated in several cell types
and diseases [34]. In this study AEA did not significantly
modulate proliferation of SF. It might be that AEA only
elicits antiproliferative effects during an inflammatory
challenge and since no cytokines were added in our own
experiments no effects were observed.
In previous studies, CB1/CB2 activation increased
integrin-driven adhesion [16]. AEA treatment of SF re-
sulted in a bell-shaped dose–response curve, which
might be due to increased activation of TRPV1/TRPA1
at high AEA levels leading to increased Ca2+
mobilization and decreased integrin affinity. At low
levels, AEA only activates CB1 and, thus, Ca
2+
mobilization would be optimal to activate integrins. The
observed differences in adhesion between OASF and
RASF in response to AEA may have several reasons. Al-
though we did not detect differences in CB1, CB2 or
TRPV1 protein levels, intracellular signaling might be
altered in RASF compared to OASF or healthy SF.
Epigenetic studies already revealed several differences
between “transformed” RASF and healthy SF [35].
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Consequently, RASF retain their invasive and migrative
phenotype when implanted in SCID mice, whereas
OASF do not demonstrate this feature [3]. As adhesion
precedes invasion and migration, the observed differ-
ences between OASF and RASF might therefore also be
due to epigenetic alterations. These changes might
manifest in differential endocannabinoid signaling in
OASF and RASF. This is further emphasized by a differ-
ent composition of endocannabinoids in healthy synovial
fluid and synovial fluid from RA patients [6].
Our in vitro findings regarding anti-inflammatory ef-
fects of AEA were also studied in the CIA model. Arth-
ritic mice benefited when treated with the FAAH
inhibitor JNJ1661010. FAAH inhibition raises EC levels
in most organs but the magnitude and composition of
EC is dependent on the FAAH inhibitor used [36]. Kin-
sey et al. used the FAAH inhibitor URB597 for the treat-
ment of CIA and found beneficial effects, which were
dependent on activation of CB2 [37]. The effects in the
present study were subtle and this likely depends on the
FAAH inhibitor used. In addition, we used a dose
(20 mg/kg) which was effective in decreasing pain in rats
but higher doses might be needed in mice due to faster
turnover or under systemic proinflammatory conditions
like in collagen-induced arthritis. In contrast to
JNJ1661010, URB597 also inhibits several other ester-
ases, some of which might also contribute to N-
acylethanolamine degradation [36].
Conclusions
This study demonstrates that cytokine production of
synoviocytes and RASF is modulated by the N-
acylethanolamines AEA, PEA and OEA in a TRPV1/
TRPA1-dependent manner. The effects of these com-
pounds were enhanced by COX-2 inhibition suggesting
a sensitizing role for COX-2-derived metabolites at
TRPs. Furthermore, AEA reduced MAP kinase signaling
and increased adhesion of SF to fibronectin. The benefi-
cial effects of elevated EC levels were demonstrated in
the CIA model in mice. These findings show that activa-
tion of the EC system can be beneficial in arthritis and
manipulation of this system (especially by combination
of a COX-2 and a FAAH inhibitor) might be a promising
strategy to reduce erosions and inflammation in
arthritis.
Additional files
Additional file 1: Visualization of CB1 (A), CB2 (B) and TRPV1 (C)
protein in RASF by western blot (whole membranes) and
immunofluorescent staining of CB1 (D) with and without blocking
peptide. A, B and C are corresponding whole membranes from blots
depicted in Fig. 2d CB1-specific antibody ab23703 was used with (right
panel) and without blocking peptide (left panel). (TIFF 13914 kb)
Additional file 2: Influence of CB1 (A, D, G), CB2 (B, E, H) or TRPV1
(C, F, I) antagonism together with anandamide (AEA) on TNF-
induced (10 ng/ml) interleukin- 6 (IL-6) (A, B, C), IL-8 (D, E, F) and
MMP-3 (G, H, I) production by RASF under hypoxic conditions. The
dotted line indicates the control level of 100 % (TNF without AEA). The
general linear model with Dunnett’s post hoc test was used for all
comparisons. All data are given as mean ± SEM. CB1 antagonist =
CP945598, CB2 antagonist = JTE-907, TRPV1 antagonist =
5’iodoresiniferatoxin. (TIFF 681 kb)
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